Munafa Stock Market Course + Intraday & FNO calls 
MA NEWS why is Mastercard Incorporated price falling or rising
MA NEWS reasons for why stock price of Mastercard Incorporated is falling or rising
MA Mastercard Incorporated is falling or rising technical reasons
Technical analysis forecast of Mastercard Incorporated Stock is that its in a uptrend for shortterm, and I will avoid taking a SHORT or SELL trade in this stock. Look for opportunities to BUY or go LONG in Mastercard Incorporated MA at this time. Stock is rising and might rise more.
It appears as if Mastercard Incorporated MA gave a large move recently.
Stock of Mastercard Incorporated (MA) is trading above an important moving average line, but it crossed this line recently, which means that it could show a small or a large fall soon enough depending on its trend.
Although my analysis for Mastercard Incorporated is bullish for shortterm, but stock is over bought and there are high chances of some profit booking tomorrow. You might want to sell the stock tomorrow in intra day with a stoploss of 572.1, for a target of 559.5 or 549.01
MA Mastercard Incorporated is falling or rising NEWS fundamental reasons
Amish Shah turns bullish on pharma, remains cautious on IT Indian equities are poised for a constructive phase, with strategists anticipating earnings acceleration and a potential revival in foreign investor interest. While near-term earnings surprises are limited, FY27 is projected to see significant growth. Phar - NEWS as on 2025-12-15 indiatimes.com
2 top stock recommendations from Rahul Sharma for near term Markets staged a strong recovery on Thursday, led by banking stocks, as the Nifty rebounded from intraday lows. Analysts noted a positive technical setup at a crucial support zone, with potential for further upside if the rebound sustains above 25,850. Eic - NEWS as on 2025-12-11 indiatimes.com
Delhi HC allows Sun Pharma to manufacture, export its own weight loss drug The Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made by Novo Nordisk as Wegovy. However, the court barred Sun from selling the drug in India until March 2026, when Novo No - NEWS as on 2025-12-10 indiatimes.com
Suzlon Energy shares are down 29% from peak but Nuvama just upgraded the stock to buy. Here's why Suzlon Energy’s sharp correction has prompted Nuvama and other brokerages to turn bullish, citing improving sector visibility, strong order inflows, export potential, and expanding manufacturing capacity, even as the stock trades below key technical levels - NEWS as on 2025-12-09 indiatimes.com
After-Hours Earnings Report for December 8, 2025 : TOL, PHR, CMP, MAMA, OOMA The following companies are expected to report earnings after hours on 12/08/2025. Visit our Earnings Calendar for a full list of expected earnings releases.Toll Brothers, Inc. (TOL)is reporting for the quarter ending October 31, 2025. The building (resid - NEWS as on 2025-12-08 nasdaq.com
Pharma firm Corona Remedies IPO to open on Dec 8; sets price band at Rs 1,008-1,062/ share Pharma firm Corona Remedies, backed by ChrysCapital, has set its IPO price band at Rs 1,008-1,062, valuing the company at nearly Rs 6,500 crore. The Rs 655.37 crore public offering, an Offer For Sale, opens December 8 and closes December 10. The company, - NEWS as on 2025-12-03 indiatimes.com
Omnicom–IPG merger: Kartik Sharma to lead India as CEO; Singh named COO; Sinha joins as strategic advisor Omnicom Media has formalised its India leadership post-merger with IPG Mediabrands, appointing Kartik Sharma as CEO. This integration strengthens Omnicom's regional footprint, positioning it more competitively against Publicis in India's media market. The - NEWS as on 2025-12-02 indiatimes.com
Cough syrup row puts regulators on overdrive to test pharma products Indian drug companies are significantly increasing product testing. This surge follows strict government rules and joint inspections by regulators. The focus is on ensuring quality after recent contamination issues. Testing volumes have jumped dramatically - NEWS as on 2025-12-02 indiatimes.com
Sun Pharma launches Ilumya for psoriasis treatment in India Sun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis. Clinical studies in India showed significant skin clearance in patients. Ilumya offers a new treatment option for th - NEWS as on 2025-12-01 indiatimes.com
More announcements and NEWS
MA Mastercard Incorporated current price & indicator signals
Recent prices of MA Mastercard Incorporated are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 12 Fri Dec 2025 | 571.93 | 565.89 to 573.71 | 1.52% | 1.47 times |
| 11 Thu Dec 2025 | 563.37 | 542.65 to 565.13 | 4.55% | 1.53 times |
| 10 Wed Dec 2025 | 538.86 | 537.50 to 544.95 | 0.24% | 1.27 times |
| 09 Tue Dec 2025 | 537.55 | 535.92 to 541.90 | -0.53% | 0.82 times |
| 08 Mon Dec 2025 | 540.44 | 537.39 to 547.33 | -0.93% | 1.03 times |
| 05 Fri Dec 2025 | 545.52 | 541.25 to 550.44 | 0.62% | 0.89 times |
| 04 Thu Dec 2025 | 542.18 | 539.56 to 559.00 | -2.09% | 0.59 times |
| 03 Wed Dec 2025 | 553.73 | 546.50 to 555.07 | 1.43% | 1.13 times |
| 02 Tue Dec 2025 | 545.91 | 541.04 to 554.75 | 0.36% | 1.29 times |
| 01 Mon Dec 2025 | 543.97 | 543.39 to 549.78 | -1.19% | 0.93 times |
| 28 Fri Nov 2025 | 550.53 | 545.42 to 551.40 | 1% | 0.53 times |
| 26 Wed Nov 2025 | 545.09 | 544.17 to 548.99 | -0.25% | 0.38 times |
Videos related to: MA NEWS why is Mastercard Incorporated price falling or rising
Hindi Video The Truth Of Stock Markets That Everyone Is Hiding From You
Hindi Basics How To Trade In FnO Futures Options Stock Market
- USA Screeners
- USA Daily Screener
- USA Weekly Screener
- USA Monthly Screener
- Support & Resistance
- USA Shares Near Support
- USA Shares Near Resistance
